STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1/ Line 3-4	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3/ Line 55-63 Page 4/ Line 77-81	Abstract/Para 2 Abstract/Para 4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 5/ Line 91-110 Page 6/ Line 111	Introduction/Para 1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 6/ Line 111-114	Introduction/Para 2
Methods				
Study design	4	Present key elements of study design early in the paper	Page 1/ Line 3-4 Page 6/ Line 117-119	Title Study design and setting/Para 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6/ Line 117-126	Study design and setting/Para 1
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	Page 7/ Line 132-136	Study Population/Para 1
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case	N/A	This study was not a matched study
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 7/ Line 141-152 Page 8/ Line 153 Page 8/ Line 155-166	Definitions/Para 1 Outcomes/Para 1
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 8/ Line 168-169	Statistical Analysis/Para 1
Bias	9	Describe any efforts to address potential sources of bias	Page 6/ Line 117-126 Page 7/ Line 138-139	Study design and setting/ Data collection/Para 1
Study size	10	Explain how the study size was arrived at	Page 6/ Line 119-125 Page 7/ Line 132-136	Study design and setting/ Study Population/Para 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 8/ Line 168-169	Statistical Analysis/Para 1

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 8/ Line 169-173 Page 9/ Line 174-189	Statistical Analysis/Para 1
		(b) Describe any methods used to examine subgroups and interactions	N/A	No subgroup analysis was applicable
		(c) Explain how missing data were addressed	Page 7/ Line 133-136	Study Population/Para 1
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	N/A	All infants were followed to NICU discharge.
		(e) Describe any sensitivity analyses	Page 9/ Line 182-189	Statistical Analysis/Para 1
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 9/ Line 193-194 Page 10/ Line 195-198 Figure 1	Results/Para 1 Figures
		(b) Give reasons for non-participation at each stage	Page 9/ Line 193-194 Page 10/ Line 195-198	Results/Para 1
		(c) Consider use of a flow diagram	Figure 1	Figures
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 10/ Line 199-211 Table 1	Results/Para 2 Tables
		(b) Indicate number of participants with missing data for each variable of interest	Table 1	Tables
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	N/A	All infants were followed until discharge.
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	Page 10/ Line 212-213 Table 2	Results/Para 3 Tables
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	Not a case-control study
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	Not a cross-sectional study
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 10/ Line 211-212 Page 11/ Line 213-217 Table 3/ Table 4	Results/Para 3 Tables
		(b) Report category boundaries when continuous variables were categorized	Page 8/ Line 165-166 Table 3/ Table 4	Statistical Analysis/Para 1 Tables
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page 10/ Line 214-215 Page 11/ Line 216	Results/Para 3
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Table 3 Table 4	Tables
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 11/ Line 229-234	Discussion/Para 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 14/ Line 293-299 Page 15/ Line 300-302	Discussion/Para 5

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 15/ Line 303-306	Discussion/Para 6
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 15/ Line 301-302	Discussion/Para 5
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 15/ Line 316-317	Acknowledgments/Para 1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/tp-22-1
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.